Conference - Events
NHS ConfedExpo 2026 is the UK’s leading health and care conference, dedicated to improving care for patients and the public.
Join over 6,800+ health and care professionals, leaders, and partners for two days of collaboration, insight, and innovation. This is your opportunity to influence the future of health and care, share good practice, and discover solutions that deliver high-quality care for all.
Be a part of the conversation shaping the future of health and care.
Recent advances in chemical biology and protein engineering are expanding the boundaries of which proteins can be modulated pharmacologically. Multifunctional small molecules (such as molecular glues, targeted protein degraders, and allosteric modulators) are enabling precise control over protein stability, localization and activity, often by exploiting endogenous cellular pathways.
In parallel, novel biologic modalities, including engineered antibodies, multi-specific binders, peptide scaffolds, nucleotide and RNA therapeutics, offer complementary strategies to engage complex or transient target surfaces with high affinity and specificity. Collectively, these approaches are reshaping early‑stage drug discovery by providing versatile platforms to modulate challenging targets through m…
The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and a new wave of next-generation solid tumor and autoimmune programs moving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy.
Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology…
Gain practical insight, fresh perspective and real-world learning to help you navigate the next phase of clinical coding with confidence. This focused, one-day, face-to-face forum brings together NHS clinical coding professionals to share proven approaches, lessons learned and strategies you can apply immediately within your own service.
Previous attendees consistently highlight the value of this annual conference for its practical relevance, knowledgeable speakers and opportunities to connect with peers facing similar challenges. Through expert presentations, shared NHS experience, interactive discussion and networking, you will leave with clearer direction on ICD-11 and OPCS-4.11, stronger approaches to workforce and hybrid working challenges, improved understanding of data quality for d…
The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programs evolve beyond first-generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through improved safety and toxicity profiles.
With an increasing number of bispecifics progressing toward the clinic, the inaugural World Bispecific Summit Europe brings Europe's bispecific leaders together for the first time, building on the proven success of the World Bispecific Summit US.
This industry-led forum delivers deep technical discussions and case studies spanning novel antibody formats, next-gen…
The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programs evolve beyond first-generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through improved safety and toxicity profiles.
With an increasing number of bispecifics progressing toward the clinic, the inaugural World Bispecific Summit Europe brings Europe's bispecific leaders together for the first time, building on the proven success of the World Bispecific Summit US.
This industry-led forum delivers deep technical discussions and case studies spanning novel antibody formats, next-gen…
The cell and gene therapy sector is accelerating faster than the systems designed to pay for it. With 39 FDA approved CGTs and more than 80 expected by 2032, the widening gap between scientific progress and pricing, policy, and reimbursement frameworks is threatening real world patient access. At the same time, the last year has brought major changes, from the Cell and Gene Therapy Access Model and outcomes based agreements to rising concerns about coverage and the policy changes still to come.
Returning to Washington DC, the 3rd Cell and Gene Therapy Pricing and Reimbursement Summit is the only meeting built specifically for cell and gene therapy biopharma, commercial and government payers, policymakers, and healthcare providers to confront these challenges head on. Through exclusive case…
Scholars Conferences is thrilled to invite you to its upcoming scientific gathering “2nd Edition World Congress on Future of Aging & Rejuvenation Science” (WCFA 2026) to be held during July 20-21, 2026 at Vienna, Austria.
The conference strives to provide a meaningful theme of “Redefining Aging: Science, Innovation, and Longevity”
The WCFA 2026 Conference aims to showcase the latest advancements in gerontology and geroscience aimed at improving health and longevity, discuss the societal implications of aging, and promote sustainable practices and policies that support aging populations in an environmentally and economically viable manner. Key themes include pioneering gerontology, integrative approaches to longevity, advancing sustainable aging, bridging research and practice, enhancin…
Maximizing the Potential of Radiopharmaceuticals through Novel Targets, Expanded Isotopes and Supply, and Enhanced Dosimetry to Drive Efficacious Therapies From Bench to Approval.
Radiopharmaceuticals are no longer an emerging promise, they are becoming a defining force in oncology. Once considered a niche modality, targeted radiopharmaceutical therapies are rapidly moving into the spotlight as one of the most promising approaches for precision cancer treatment. With major pharmaceutical companies investing heavily, pipelines expanding at pace, and clinical successes demonstrating the power of targeted radiation delivery, the field is transitioning from early validation to scale.
Momentum across the sector is undeniable. Breakthrough therapies continue to advance through the clinic, alpha-…
Over the past year, the Myasthenia Gravis landscape has transformed from a once-sparse market into a highly competitive, multi-billion-dollar arena, driven by breakthroughs in FcRn inhibition, complement targeting and B-cell modulation. This surge has sparked growing interest in applying these approaches to adjacent neuromuscular and peripheral nerve disorders, yet critical gaps in disease biology, patient stratification and biomarker validation continue to limit clinical success.
The Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit is the first industry-led forum dedicated to transforming the MG, CIDP, GBS and MMN treatment landscapes, bringing together biopharma leaders to tackle the mechanistic and translational challenges shaping this rapidly evolving space.&n…
ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution is placing unprecedented pressure on linker architecture and conjugation chemistry to control stability, reduce off-target toxicity, overcome tumor resistance, and maintain manufacturability.
To meet these challenges head on, the 4th ADC Linker and Conjugation Summit offers a highly technical, deeply curated environment built specifically for specialists working at the cutting edge of ADC chemistry. At this summit, you aren't lost in a crowd, you're surrounded by peers who share the same job titles, scientific focus, and day-to-day challenges. Every session is built for specialists, every con…
Don’t miss the chance to attend the Marcus Evans 14th Edition Medical Device Safety Monitoring and Reporting conference taking place in San Diego between August 11-12! This event will offer attendees current knowledge and practical lessons on advancing routine monitoring and surveillance practices, while exploring new and emerging technologies and workflows. Attendees will be able to discuss how they can implement improvements on post market surveillance, reporting and complaint handling whilst avoiding uncertainties and risks that come from new technologies and automation techniques including AI.
Attending This Premier marcus evans Conference Will Enable You to:
Determine and define the optimal standards for medical device post-market monitoring beyond the minimum regulatory standa…
Don’t miss the chance to attend the Marcus Evans 14th Edition Medical Device Safety Monitoring and Reporting conference taking place in San Diego between August 11-12! This event will offer attendees current knowledge and practical lessons on advancing routine monitoring and surveillance practices, while exploring new and emerging technologies and workflows. Attendees will be able to discuss how they can implement improvements on post market surveillance, reporting and complaint handling whilst avoiding uncertainties and risks that come from new technologies and automation techniques including AI.
Attending This Premier marcus evans Conference Will Enable You to:
Determine and define the optimal standards for medical device post-market monitoring beyond the minimum regulatory standa…
The external landscape for biopharma continues to shift as organizations navigate workforce restructuring, evolving therapeutic priorities, and increasing pressure to operate more efficiently. As the backbone of scientific support, lab operations and facilities professionals are being asked to do more with less, managing complex R and D environments, maintaining compliant and safe laboratories, and optimizing resources to ensure research continues without disruption.
The 3rd Lab Ops and Facility Management for Biopharma West Summit will unite 70+ senior lab operations and facilities professionals from leading biotech and pharma organizations to discuss how to run smarter, more resilient laboratories. Across three days, attendees will explore strategies to integrate automation into th…
The Global Infectious Diseases and One Health Conference (GIOH 2026) in London, United Kingdom, Online from August 17–19, 2026, unites health professionals, scientists, and policymakers committed to strengthening preparedness against infectious threats. The One Health congress offers a global perspective on how collaborative efforts can prevent and mitigate disease outbreaks.
Core discussions will focus on pandemic intelligence, surveillance systems, climate-driven infections, biosecurity frameworks, and antibiotic stewardship. Renowned experts will share strategies that enhance early detection, containment, and cross-sector coordination.
Participants will gain access to interactive workshops, expert dialogues, and live demonstrations showcasing new technologies that transform infectious d…
The Global Public Health and Epidemiology Congress (G-PHEC 2026) will take place from August 17–19, 2026, in London, United Kingdom, with a hybrid format offering both in-person and online participation.
The GloNurse Summit 2026, officially known as the Global Nursing Congress and Healthcare Innovation Summit, will take place August 17–19, 2026, in London, UK, and online. The Nursing Conferences aims to redefine global healthcare through innovation, evidence-based nursing, and cross-disciplinary collaboration.
Attendees for Nursing Science Event will explore topics such as ecosystems, leadership in nursing practice, global health education, patient engagement digital health, and mental health care reform. The conference will feature international speakers, academic researchers, policy experts, and frontline practitioners sharing insights on modern healthcare challenges and opportunities.
The Nursing Congress hybrid setup allows both physical and virtual attendees to benefit from networking…
The 6th Rare and Genetic Kidney Disease Drug Development Summit is the industry's only meeting dedicated exclusively to advancing therapies across IgAN, FSGS, ADPKD, Alport syndrome, C3G, and related renal indications. Bringing together leaders from biopharma, academia, and patient advocacy, this summit spans discovery through commercialization to support smarter, faster decision-making across kidney disease pipelines.
As competition intensifies in rare and genetic kidney disease drug development, companies are under increasing pressure to differentiate assets, generate robust clinical evidence, and accelerate timelines to patients. Accelerated approval pathways have fundamentally reshaped how teams approach target evaluation, surrogate endpoint selection, and trial design within small, he…
Oligonucleotide R and D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.
Building on last year's momentum, the 6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevel…
AI/ML and computational use cases for biologics design and optimization are at a critical turning point. Latent Labs' launch to develop biologics using advanced AI models, Eli Lilly's TuneLab partnering with BigHat Bio and Chai Discovery, and Bayer's collaboration with Cradle on AI-enabled antibody discovery, emphasize the role of AI as the key accelerant in re-architecting biologics workflows to expedite discovery to lead candidate optimization.
The re-imagined CDD and AI for Biologics Summit returns at this industry-defining moment to deliver key learnings on applied, experimentally validated use cases to support you in catalyzing biologics discovery innovation. Dive into the convergence of computational drug design and AI applications in de novo protein design, property prediction, mult…
